Healthcare company Viatris Inc (NASDAQ:VTRS) on Wednesday announced positive top-line results from a Phase 3 study of EFFEXOR (venlafaxine) in Japanese adults with generalised anxiety disorder (GAD).

The study demonstrated the efficacy and safety of EFFEXOR in treating GAD, meeting both primary and secondary endpoints and confirming superiority compared to placebo.

Viatris plans to submit the results to the Pharmaceuticals and Medical Devices Agency (PMDA) in 2025.

EFFEXOR is currently approved in Japan for the indication of major depressive disorder in adults. For the indication of GAD, EFFEXOR has been approved in more than 80 countries outside of Japan.